Breaking News, Collaborations & Alliances

Vanda & AnaptysBio Partner for the Development and Commercialization of Imsidolimab

Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.

Author Image

By: Charlie Sternberg

Associate Editor

Vanda Pharmaceuticals Inc. and AnaptysBio Inc. have announced an exclusive, global license agreement for the development and commercialization of imsidolimab (IL-36R antagonist mAb), which has successfully completed two registration-enabling global Phase 3 trials evaluating the safety and efficacy of imsidolimab in patients with Generalized Pustular Psoriasis (GPP). GPP is a rare skin disorder caused by mutations in the IL36RN gene, which codes for a protein regulating the IL-36 cytokines. Th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters